DRUG DISCOVERY -Targeting mRNA stability
Novation's approach is applicable to all mRNAs containing specific stability control elements (SCEs). Novation's scientists seek to identify small molecular weight drugs which are able to reset the abnormal stabilisation of certain disease mediating mRNAs. By reactivating the degradation of inappropriately stabilised mRNA, the stimulus for a disease is removed and thus the disease alleviated.
Novation has patented a unique series of cell-based High Throughput Screening (HTS) assays, the QUEST
technology, which will enable the identification of new small molecule therapeutics for high interest gene targets. The molecules selected are specific for the target of interest and do not interfere with mRNA not containing these SCEs.